Moody’s sees low cost of debt driving M&A, but investors may push for other uses

The pharmaceutical and consumer products sectors are well set to take advantage of the low cost of debt for M&A activity in the next 12-18 months, according to a report published on Thursday by credit rating agency Moody’s. But the actions of some companies suggest a different approach.